## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CEIVED

Applied ITANGE A. Mizzen et al.

Art Unit : 1631

Serial No.: 08/977,787

Examiner: Mary Zeman

MAR 1 5 2002

Filed

: November 25, 1997

Title

: IMMUNE RESPONSES USING COMPOSITIONS CONTAINING CHICENTER 1600/2900

**PROTEINS** 

Commissioner for Patents Washington, D.C. 20231

## RESPONSE

In response to the Office action mailed August 28, 2001, please amend the application as follows and consider the remarks below.

## In the claims:

Please cancel claims 70-87 and add new claims 88-124.

8. The fusion protein of claim 68, wherein the cell mediated immune response is a class I-restricted T cell response.

- 89. The fusion protein of claim 68, wherein the cell mediated immune response is a class II-restricted T cell response.
- 90. The fusion protein of claim 59, wherein the CTL epitope is a class I-restricted T cell epitope.
- 91. The fusion protein of claim 59, wherein the CTL epitope is a class II-restricted T cell epitope.
  - 92. The fusion protein of claim 62, wherein the stress protein is hsp65.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents. Washington, D.C. 20231.

Date of Deposit

Cinnatura

Typed or Printed Name of Person Signing Certificate